SeeThruEquity Initiates Coverage on Avant Diagnostics, Inc. (OTCQB: AVDX) with a Price Target of $2.97

NEW YORK, NY / ACCESSWIRE / March 10, 2016 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated coverage on Avant Diagnostics, Inc. (OTCQB: AVDX) with a price target of $2.97.

The report is available here: AVDX Initiation Report. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack’s. The report will be available on these platforms. The firm also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

Avant Diagnostics’ solution is to utilize the technology that it exclusively licensed from Wayne State University and seek the new research methods in the diagnostics industry. The Company’s goal is to commercialize microarray-based diagnostic tests and services that aim to detect diseases at an early-stage with pre-symptomatic screening. These novel methods are based on patented and proprietary techniques that are suitable to be run in a central or regional laboratory utilizing samples from healthcare providers in the U.S. and sent to the authorized CLIA/ISO-certified testing facility for future research. Avant’s goal is to become a leading facility in the early-detection process by building a pipeline of 4-6 diagnostic tests in 12-18 months through organic development and acquisitions of other techniques focused on early detection and pre-symptomatic screening.

“According to BCC Research, a leading publisher of technology market reports, the global ovarian cancer drug and the diagnostic market will be reaching $34.6 billion by 2018, representing a compound annual growth rate of 13.1% between 2013 and 2018. The primary driver for this market is the high prevalence of ovarian cancer among women. Ovarian cancer is associated with high morbidity and mortality rate because the majority of patients are diagnosed at a later stage. The survival rate drops significantly as the current medical treatments fail to detect ovarian cancer at an early stage. Early detection has a 5-year survival rate of 93%, but late-stage symptoms only have a 5-year survival rate of 18%. The lack of early symptoms and effective diagnostic tests make ovarian cancer the 5th most common cancer in the U.S. Avant’s sophisticated product, OvaDx®, can potentially mitigate this issue by detecting an ovarian tumor in the early stage, which will significantly increase survival rates,” commented Ajay Tandon, CEO of SeeThruEquity. “We are initiating coverage with a 12-month price target of $2.97 per share.”

Additional highlights from the report are as follows:

Large addressable market

Avant Diagnostics has identified a large, addressable market – namely a $34.6 billion ovarian cancer drug and diagnostics market. Ovarian cancer is the 5th most common cancer in the U.S, and ~20,000 women will be diagnosed with ovarian cancer annually. Avant Diagnostics’ main product aims to detect an ovarian tumor in its early stage using microarray-based techniques, which can significantly increase the cure and survival rates for ovarian cancer patients.

Impending merger with Amarantus Diagnostics

Amarantus Bioscience Holdings, Inc. (OTCQX: AMBS), a biotechnology company that develops medical treatments that focus on Regenerative Medicine, Neurology and Orphan diseases, announced that it has entered into a Letter of Intent to acquire and merge its wholly-owned subsidiary, Amarantus Diagnostics, into Avant Diagnostics. The merger will create mutual benefits, as AMBS will assist AVDX to further commercialize resources, to accelerate the monetization of the products and Avant will improve AMBS’s technology in the diagnostic industry.

AVDX and Amarantus Diagnostics to combine with Theranostics Health

Avant and Amarantus Diagnostics, a wholly-owned subsidiary of Amarantus BioScience Holdings, announced they have jointly entered into a Letter of Intent for Avant to acquire assets and certain liabilities of Theranostics Health Incorporated. The combined company will have a robust pipeline of oncology and neurology diagnostics, with 3 proprietary diagnostic tests for ovarian cancer, multiple sclerosis, and Alzheimer’s disease. The business combination would have 7 of top 10 pharmaceutical companies as customers and the possibility of $1.5M in revenue in 2016. The combined entity would also provide a sales channel for the Alzheimer LymPro Test.

Strong patent positions

Based on 10+ years of research and development, Avant has exclusive license rights to the trade secrets and protocols required for the sale and use of the OvaDx® ovarian cancer test.

Please review important disclosures at www.seethruequity.com.

About Avant Diagnostics, Inc.

Avant Diagnostics’ solution is to utilize the technology that it has exclusively licensed from Wayne State University to exploit the new opportunities in the diagnostics industry. The Company was created to specifically commercialize microarray-based diagnostic tests and services that are focused on early detection and pre-symptomatic screening. These new tests are based on patented and proprietary technology that is suitable to be run in a central or regional laboratory utilizing samples that are collected by healthcare providers and sent to the authorized CLIA/ISO-certified testing facility for processing.

For more information, please visit the Company’s website at www.avantdiagnostics.com.

About SeeThruEquity

SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and is unbiased. The company does not conduct any investment banking or commission based business. SeeThruEquity is approved to contribute its research to Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks, and distribute its research to its database of opt-in investors. The company also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

For more information visit www.seethruequity.com.

Contact:

Ajay Tandon
SeeThruEquity
info@seethruequity.com

SOURCE: SeeThruEquity

ReleaseID: 437698